drugset
drugset / Trial / NCT04930354

ECP-1014 Treatment for Patients With Solid Tumor Cancers

NCT04930354 ↗

Phase 1 Unknown 29 enrolled Euclises Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and optimal recommended Phase 2 dose (RP2D) during a 28-day dosing period of ECP-1014 in patients with solid tumors and by evaluation of dose limiting toxicities.

Timeline

Start
2023-05
Primary completion
2023-09
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ECP-1014 Unknown 10 mg Oral
Subject ECP-1014 Unknown 20 mg Oral
Subject ECP-1014 Unknown 40 mg Oral
Subject ECP-1014 Unknown 80 mg Oral
Subject ECP-1014 Unknown 160 mg Oral

Indications

cancer